AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal
AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth …
Post
-
-
Myasthenia gravis market to reach $10.3bn across 7MM by 2034
The myasthenia gravis (MG) market across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the …
-
Bharat Biotech acquires licence for GSK’s Shigella vaccine development
GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for continued development and distribution in low and middle-income …
-
Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger adults
The US Food and Drug Administration (FDA) has expanded approval of Moderna’s respiratory syncytial virus (RSV) vaccine to include younger …
-
Debiopharm and Alkyon link for radioligand therapies development
Debiopharm has entered a co-research agreement with Alkyon Therapeutics to explore the potential of developing targeted radioligand therapies (RLTs). The partnership …
-
FDA approves label expansion of AbbVie hepatitis C therapy
The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir) for treating adults and paediatric …
-
BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisition
BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its strategy …
-
Wes Streeting: £29bn NHS boost ‘substantial’ but reform still needed
A £29bn investment into the National Health System (NHS) is ‘substantial’, but reform of the system is essential to ‘fix …
-
Vaccine sceptics among new members hired by RFK Jr for CDC’s vaccine panel
US Health Secretary Robert F Kennedy (RFK) Jr has appointed eight new members to the vaccine advisory panel at the …
-
Vutrisiran marks first silencer approved for ATTR-CM
Transthyretin amyloidosis (ATTR) is a protein conformational disorder caused by the build-up of transthyretin, the protein carrying thyroxine and retinol …
-
Enterome to advance EO2463 immunotherapy with $19m funding
Enterome has secured $19m in new private funding to progress its EO2463 OncoMimics immunotherapy, targeting indolent non-Hodgkin's lymphoma (iNHL). The funding …
-
Customs simplified: the need to streamline pharma shipments
Pharmaceutical supply chains continue to be disrupted by a range of geopolitical factors, including global conflict, economic uncertainty, and especially …
-
Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs
Novo Nordisk is eyeing a cardiometabolic drug market future that is not purely dominated by incretins, after signing a $812m …
-
FDA approves Capsida’s CAP-003 gene therapy for Parkinson’s
The US Food and Drug Administration (FDA) has approved Capsida Biotherapeutics' investigational new drug (IND) application for CAP-003 to treat …
-
SpliceBio secures $135m for gene therapy development
SpliceBio has closed a Series B financing round, raising $135m for the clinical development of SB-007, its gene therapy candidate …
